JACKSON, Mich., Oct. 10, 2024 /PRNewswire/ -- CMS Energy announced today it will provide 2024 third quarter results along with a business and financial outlook at 9:30 a.m. EDT on Thursday, October 31, 2024. A webcast of the presentation will be available on CMS Energy's website, cmsenergy.com. An audio replay will be available approximately three hours after the webcast and will be archived for 30 days on CMS Energy's website in the "Investor Relations" section. CMS Energy (NYSE: CMS) is a Michigan-based e ...

Core Insights - HeartCore Enterprises, Inc. has achieved the top market share in sales value for its Content Management System (CMS) in Japan for nine consecutive years, holding a 15.1% market share compared to the second contender at 12.5% [1][2] - Over 700 Japanese companies have adopted HeartCore's CMS, reflecting strong confidence in the platform [2][3] - The company has reported two consecutive quarters of profitable performance in its software division, driven by proactive cost reduction initiatives and sales growth [2][3] Company Developments - HeartCore launched a Management Screen Builder feature in December, enhancing website operation capabilities and driving innovation [3] - The acquisition of Sigmaways and Sabatini Global last year has positively impacted HeartCore's growth, with a focus on exploring additional synergistic opportunities for global market expansion [3] - HeartCore offers a range of services including Software as a Service (SaaS) solutions, data analytics, customer experience management, and digital transformation services [4]

Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate A HCPCS code has also been assigned to Vafseo to facilitate reimbursement at dialysis organizations CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Center for Medicare & Med ...

NEW YORK and TOKYO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) ("HeartCore" or "the Company"), a leading enterprise software and data consulting services company based in Tokyo, announced it has been awarded a new contract from Fourmix Co., Ltd. ("Fourmix"), a Japanese IT and web development company. Partnership Logo Through this contract, HeartCore will implement its CMS platform to enhance Fourmix's web development and digital marketing domain capabilities. HeartCore will ...

Core Viewpoint - CMS Energy Corporation is systematically investing in operations to enhance service quality and expand its renewable energy portfolio while phasing out coal generation [1] Group 1: Investment and Growth Plans - CMS Energy plans to invest $17 billion in capital expenditures from 2024 to 2028 to renovate infrastructure and boost clean power production [2] - The company aims to install approximately 8,000 MW of solar production by 2040 and will begin deploying battery storage, targeting 75 MW by 2027 and an additional 475 MW by 2040 [3] - An 85-megawatt solar array is planned at the former D.E. Karn coal-generating plant, expected to be operational by 2026, which will diversify the renewable energy portfolio [3] Group 2: Operational Resilience and Cost Management - CMS Energy is focusing on enhancing grid resilience to reduce outages and protect infrastructure from extreme weather, which will lower operating costs and increase revenue [4] - The company is expected to incur $238 million in costs between 2024 and 2028 to comply with environmental regulations regarding coal ash disposal [5] Group 3: Market Performance - Over the past three months, CMS Energy's stock has increased by 18.8%, outperforming the industry growth of 12.8% [7]

TI AND FOR 1 11:10 THE HD imantsu With the recent rise in the utility segment valuations as investors prepare for the strong potential of lower competitive interest rates, CMS Energy Co (NYSE:CMS) stock price has been strong. This has led to an overabundance of "Hold" recommendations for CMS stock. However, for long-term investors, CMS should be viewed as a highquality selection, both in earnings and dividend production and, more importantly, in its supportive regulatory background. I do not own the common ...

Core Insights - Abeona Therapeutics announced that the Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code ICD-10-PCS for prademagene zamikeracel (pz-cel), an investigational gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) [1] - CMS assigned Medicare reimbursement for pz-cel to Pre-Major Diagnostic Category, Medicare Severity Diagnosis Related Group 018, which is among the highest reimbursement levels for cell and gene therapies, effective October 1, 2024 [2] - The Chief Commercial Officer of Abeona expressed confidence in securing access and reimbursement for RDEB patients following favorable Medicare decisions and positive feedback from commercial payers [3] Product Overview - Prademagene zamikeracel (pz-cel) is an autologous cell-based gene therapy designed to treat RDEB, a rare connective tissue disorder caused by a defect in the COL7A1 gene [4] - Pz-cel aims to incorporate the functional COL7A1 gene into a patient's skin cells, enabling long-term gene expression and facilitating wound healing [4] - The pivotal Phase 3 VIITAL™ study evaluated pz-cel's efficacy, safety, and tolerability in 43 large chronic wound pairs among 11 subjects with RDEB [4] Company Background - Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [5] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which supports the production of pz-cel for clinical trials and potential commercial use [5] - Abeona's development portfolio includes AAV-based gene therapies for ophthalmic diseases, utilizing next-generation AAV capsids to improve treatment efficacy [5]

Multiple AI-powered features and seamless CMS integration influence Sitefinity Insight's status as a RealCDP™ BURLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Progress (Nasdaq: PRGS), the trusted provider of AI-powered infrastructure software, today announced that Progress® Sitefinity Insight® customer data platform (CDP) has been certified by the Customer Data Platform (CDP) Institute as a RealCDP™ for meeting specific standards and capabilities that are essential for managing and utilizing customer da ...

Core Insights - NorthStar Clean Energy has launched the Newport Solar project, a 180 MW initiative aimed at providing renewable electricity for General Motors' facilities in the MISO territory, highlighting a commitment to renewable energy solutions and a low carbon future [1][3] - The Newport Solar project is part of General Motors' strategy to reduce Scope 2 energy emissions globally, which includes sourcing renewable electricity and enhancing energy efficiency [3][4] Project Details - The Newport Solar facility is expected to generate approximately 410,000 megawatt-hours of renewable energy annually, equivalent to the electricity needs of over 30,000 Arkansas homes [4] - Under a 15-year renewable energy purchase agreement, the renewable energy credits from this facility will have an environmental impact comparable to planting nearly 5 million trees [4] Company Background - NorthStar Clean Energy operates over 1,500 megawatts of generating capacity across the U.S., with a development pipeline of 1 gigawatt of renewable energy [5] - The company plans to convert its coal-fired power plant into a 60 MW biomass-fueled facility capable of capturing 500,000 tons of CO2 annually, marking a significant step in bioenergy with carbon capture and storage (BECCS) projects in the U.S. [5]

Core Viewpoint - Therma Bright Inc. has received a positive notification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) regarding the pending permanent CPT® and HCPCS codes for its Venowave VW5 device, which is expected to enhance market opportunities for the company and its stakeholders [2][3][4]. Group 1: Company Update - The CMS is anticipated to provide permanent CPT® and HCPCS codes for the Venowave VW5 device in the coming days, which will cover ten health-related and CMS reimbursable indications [3][4]. - The ten indications include prevention and management of deep vein thrombosis (DVT), treatment of lymphedema, and enhancement of blood circulation, among others [4]. - The CDC estimates that over 900,000 U.S. citizens are affected by DVT and pulmonary embolism (PE) annually, indicating a significant market need for the Venowave device [4]. Group 2: Market Potential - The global market for deep vein thrombosis is projected to reach USD $1.26 billion by 2028 and USD $1.554 billion by 2032, highlighting substantial growth potential for Therma Bright's offerings [4]. - The anticipated CMS codes are expected to create a favorable environment for the company, its customers, and reseller partners, enhancing overall market presence [4]. Group 3: Leadership Statement - The CEO of Therma Bright expressed optimism regarding the upcoming confirmation from CMS and plans to announce the details of the permanent codes immediately upon receipt [5].